Joint Stock Quote (NASDAQ:JYNT) Updated by Zacks Investment Research


Spouse (NASDAQ:JYNT – Get Note) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note released Thursday to investors, Zacks.com reports.

According to Zacks, “The Joint Corp. is a healthcare franchisor of chiropractic clinics. The company’s plans include: Single Visit, Premium Wellness Plan, and Wellness Plan. It also offers a family wellness plan. The Company also ensures the elimination of subluxations. It operates its clinics across: Albany, New York; Austin, TX; Brentwood, California; Fort Mill, South Carolina; Lubbock, TX; Lynnwood, Washington; Middletown, New Jersey; San Antonio, TX; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. “

A number of other research analysts also commented on JYNT. Craig Hallum reduced his price target on Joint from $117.00 to $90.00 in a Monday, January 24 report. DA Davidson reduced its price target on Joint from $128.00 to $69.00 and set a “buy” rating for the company in a Friday, February 25 report. StockNews.com upgraded Joint from a “sell” rating to a “hold” rating in a Friday, April 22 report. Lake Street Capital lowered its price target on Joint from $150.00 to $100.00 in a Friday, February 25 research report. Finally, B. Riley lowered his price target on Joint from $125.00 to $88.00 in a Friday, February 25 research report. Three analysts gave the stock a hold rating and five gave the stock a buy rating. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $85.33.

Shares of Joint stock opened at $31.31 on Thursday. The company has a market capitalization of $451.27 million, a price-earnings ratio of 65.23 and a beta of 1.27. The company has a debt ratio of 0.07, a current ratio of 1.25 and a quick ratio of 1.25. Joint has a 52-week low of $29.84 and a 52-week high of $111.06. The stock has a 50-day simple moving average of $36.26 and a 200-day simple moving average of $58.12.

Joint (NASDAQ:JYNT – Get Rating) last reported quarterly results on Thursday, February 24. The company reported earnings per share (EPS) of $0.01 for the quarter, missing Thomson Reuters consensus estimate of $0.08 per ($0.07). Joint had a net margin of 8.82% and a return on equity of 26.30%. The company posted revenue of $22.43 million for the quarter, versus analyst estimates of $22.21 million. In the same quarter of the previous year, the company had earned earnings per share of $0.12. As a group, equity research analysts expect Joint to post 0.33 earnings per share for the current year.

In other news, CEO Peter D. Holt bought 1,500 shares of the company in a deal that took place on Wednesday, March 16. The shares were acquired at an average price of $33.24 per share, for a total transaction of $49,860.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. Additionally, CFO Jake Singleton bought 1,515 shares of the company in a trade that took place on Wednesday, March 16. The shares were purchased at an average price of $33.00 per share, for a total transaction of $49,995.00. Disclosure of this purchase can be found here. 6.10% of the shares are currently held by company insiders.

Several large investors have recently increased or reduced their stake in JYNT. Captrust Financial Advisors increased its holdings of Joint stock by 117.6% in Q3. Captrust Financial Advisors now owns 285 shares of the company valued at $28,000 after buying an additional 154 shares in the last quarter. Pinebridge Investments LP acquired a new stake in Joint in Q4 valued at approximately $33,000. Point72 Hong Kong Ltd acquired a new stake in Joint in Q4 worth approximately $36,000. Marshall Wace North America LP acquired a new stake in Joint in Q1 worth approximately $47,000. Finally, USA Financial Portformulas Corp acquired a new stake in Joint in Q3 valued at around $59,000. Institutional investors and hedge funds hold 86.71% of the company’s shares.

Joint venture profile (Get a rating)

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics. The Company operates through two segments, corporate clinics and franchise operations. It operates through direct ownership, management arrangements, franchises and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States.

See also

Get a Free Copy of Zacks Research Report on Joint (JYNT)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Analyst Recommendations for Joint (NASDAQ:JYNT)



Get news and reviews for Joint Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for joint and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.